Guggenheim Upgrades Bristol-Myers Squibb to Buy, Announces $62 Price Target

Benzinga · 1d ago
Guggenheim analyst Seamus Fernandez upgrades Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy and announces $62 price target.